News

News

Immunovant Sciences Ltd. Closes Transaction with Health Sciences Acquisitions Corporation

Immunovant Sciences Ltd. Closes Transaction with Health Sciences Acquisitions Corporation Combined company, to be named Immunovant, Inc., will begin trading on Nasdaq under ticker symbol

0 comments

Health Sciences Acquisitions Corporation Sets Date for Special Meeting of Stockholders to Vote on Transaction with Immunovant Sciences Ltd.

Health Sciences Acquisitions Corporation Sets Date for Special Meeting of Stockholders to Vote on Transaction with Immunovant Sciences Ltd. NEW YORK – Health Sciences Acquisitions

0 comments

Immunovant Initiates Dosing in ASCEND-GO 2, a Phase 2b Trial of IMVT-1401 in Patients with Graves’ Ophthalmopathy (GO)

Immunovant Initiates Dosing in ASCEND-GO 2, a Phase 2b Trial of IMVT-1401 in Patients with Graves’ Ophthalmopathy (GO) IMVT-1401, a fully human anti-FcRn antibody designed

0 comments

Health Sciences Acquisitions Corporation and Immunovant to Host Joint Conference Call for the Investment Community on Friday, October 11, at 8:30am EDT

Health Sciences Acquisitions Corporation and Immunovant to Host Joint Conference Call for the Investment Community on Friday, October 11, at 8:30am EDT NEW YORK and

0 comments

Immunovant To Merge with Health Sciences Acquisitions Corporation, Creating New Publicly-Listed FcRn-Focused Company

Immunovant To Merge with Health Sciences Acquisitions Corporation, Creating New Publicly-Listed FcRn-Focused Company Top shareholders of Immunovant post-closing to include Roivant Sciences and blue-chip biotech

0 comments

Immunovant Appoints Robert K. Zeldin as Chief Medical Officer and W. Bradford Middlekauff as General Counsel

Immunovant Appoints Robert K. Zeldin as Chief Medical Officer and W. Bradford Middlekauff as General Counsel NEW YORK and BASEL, Switzerland, August 13, 2019 /PRNewswire/

0 comments

Immunovant Appoints Pete Salzmann as Chief Executive Officer

Immunovant Appoints Pete Salzmann as Chief Executive Officer NEW YORK and BASEL, Switzerland, June 5, 2019 /PRNewswire/ — Immunovant, a biopharmaceutical company focused on developing innovative therapies for patients

0 comments

Immunovant Initiates Dosing in ASCEND-GO 1, a Phase 2a Trial of IMVT-1401 in Patients with Graves’ Ophthalmopathy (GO)

Immunovant Initiates Dosing in ASCEND-GO 1, a Phase 2a Trial of IMVT-1401 in Patients with Graves’ Ophthalmopathy (GO) IMVT-1401, a fully human anti-FcRn antibody administered

0 comments

Immunovant to Present Phase 1 Clinical Trial Results at 2019 American Academy of Neurology Annual Meeting

Immunovant to Present Phase 1 Clinical Trial Results at 2019 American Academy of Neurology Annual Meeting First poster presentation on IMVT-1401, a fully human anti-FcRn

0 comments

Roivant Sciences Enters into Development Partnership with HanAll Biopharma

Roivant Sciences Enters into Development Partnership with HanAll Biopharma BASEL, Switzerland, Dec. 19, 2017 /PRNewswire/ — Roivant Sciences and HanAll Biopharma Co., Ltd. announced today

0 comments